Spots Global Cancer Trial Database for MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Official Title: A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Study ID: NCT01240928
Conditions
Study Description
Brief Summary: This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.
Detailed Description: The phase II portion of this trial will be listed under a separate NCT number.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Contact Details
Name: Vandana Abramson, MD
Affiliation: Vanderbilt-Ingram Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
